Neoplasms

All Conditions

Rare Diseases

Sarcoma

Desmoplastic Small Round Cell Tumor

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Irinotecan

Bevacizumab

Temozolomide

Alkylating Agents

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Topoisomerase I Inhibitors

Enzyme Inhibitors

Antineoplastic Agents, Alkylating

This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.

Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.

irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator

Emily Slotkin, MD

This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT

In patients with measurable disease. added to the initial treatment of patients with Desmoplastic small round cell tumor (DSRCT)

with the addition of irinotecan, temozolomide and bevacizumab to the initial treatment of patients with DSRCT

as an early indicator of response in those patients with measurable or evaluable disease

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor	NCT01189643	Sarcoma Desmoplastic Sm...	irinotecan, tem...	1 Year - 29 Years	Memorial Sloan Kettering Cancer Center
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor	NCT01189643	Sarcoma Desmoplastic Sm...	irinotecan, tem...	1 Year - 29 Years	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator